INTENT-Muscle (A Sub-study of INTENT)

Critically Ill Clinical Trial

Official title:

Intensive Nutrition Therapy Compared to Usual Care in Critically Ill Adults: A Randomised Pilot Trial - Muscle (a Sub-study of INTENT)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04896515
• Other study ID #: ANZIC-RC/ER003
• Status: Completed
• Start date: June 21, 2021
• Est. completion date: February 27, 2023

Study information

• Verified date: May 2024
• Source: Australian and New Zealand Intensive Care Research Centre
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The currently recruiting randomised controlled trial "Intensive Nutrition Therapy Compared to Usual Care in Critically Ill Adults" (INTENT, NCT03292237) is the first multi-centre trial to compare an intensive, individualised nutrition intervention to standard care for the duration of hospital admission in critically ill patients. INTENT-Muscle, is an observational longitudinal study nested within INTENT. The aim of INTENT-Muscle is to compare longitudinal changes in muscle health (assessed by bioimpedance and muscle ultrasound) in critically ill patients randomised to each arm of INTENT.

Description:

Background: Critically ill patients may experience debilitating loss of muscle mass and strength, leading to substantial functional impairments both during and long after hospitalisation. Little is known about what therapies may attenuate deterioration of muscle health (muscle mass and muscle quality) in this setting but nutrition is thought to be important, based on the physiological response to critical illness.

The currently recruiting randomised controlled trial (RCT) "Intensive Nutrition Therapy Compared to Usual Care in Critically Ill Adults" (ClinicalTrials.gov Identifier: NCT03292237) is the first multi-centre trial to provide an individualised nutrition intervention for the duration of hospital admission in critically ill patients. Combining the most promising and novel bedside techniques for objectively measuring muscle health (bioimpedance technology and ultrasound) with a whole hospital nutrition intervention has never been done before, and will provide crucial data to understand the relationship between nutrition delivery and changes in muscularity from ICU admission to hospital discharge.

Aim: To explore changes in muscle health in response to an individualised nutrition intervention and in association with clinical and functional outcomes, using clinically applicable bedside techniques.

Secondary aims:

In both arms of INTENT to:

1. Compare longitudinal changes in bioimpedance variables (fat-free mass, normally hydrated lean tissue, extracellular/intracellular ratio, and variables from Cole modelling) to hospital discharge (or day 28)

2. Compare longitudinal changes in ultrasound variables (mid-upper arm and quadriceps muscle thickness, rectus femoris cross-sectional area, and rectus femoris echogenicity) to hospital discharge (or day 28)

3. Compare clinical and functional outcomes in patients identified as having low muscularity (assessed by ultrasound) at ICU admission

4. Investigate the relationship between bioimpedance and ultrasound variables with clinical and functional outcomes at baseline and over the hospital admission (collected as part of INTENT)

Hypothesis: In critically ill patients receiving individualised nutrition care for the duration of hospital admission (censored at study day 28), declines in phase angle and muscle health will be attenuated compared to patients receiving standard nutritional care.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: February 27, 2023
• Est. primary completion date: February 27, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Randomised to the INTENT trial at a participating sub-study site

Exclusion Criteria:

• Patients will be excluded from the sub-study if they have any of the following:

• A pacemaker or electronic implantable device

• Missing limb(s)

• Unable to get adequate separation in the limbs (e.g. severe obesity)

• Inaccessible site(s) for electrode placement (e.g. major burns, trauma)

• Broken skin at the site(s) of electrode placement

• The treating clinician does not believe the study to be in the best interest of the patient

• Person responsible/Medical treatment decision maker is of non-English speaking background (therefore cannot provide informed consent) Note Before: If the Person responsible/medical treatment decision maker is of English speaking background but the patient is not (and the Person responsible/Medical treatment decision maker speaks the same language as the patient) you may continue assessing the patient for eligibility to INTENT-Muscle as the Person Responsible/Medical treatment decision maker can translate the Patient Information and Consent Form (PICF) and consent discussion with the patient in order to obtain continuing consent)

Related Conditions & MeSH terms

• Critical Illness
• Critically Ill

Intervention

Dietary Supplement:
• Supplemental parenteral nutrition
Supplemental parenteral nutrition OLIMEL N12E (Baxter Healthcare Corporation)

Locations

Country	Name	City	State
Australia	Ballarat Base Hospital	Ballarat	Victoria
Australia	Blacktown Hospital	Blacktown	New South Wales
Australia	Frankston Hospital	Frankston	Victoria
Australia	Nepean Hospital	Kingswood	New South Wales
Australia	The Alfred Hospital	Melbourne	Victoria
New Zealand	Auckland Hospital (CVICU)	Auckland

Sponsors (1)

Lead Sponsor	Collaborator
Australian and New Zealand Intensive Care Research Centre

Countries where clinical trial is conducted

Australia,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase angle	To compare longitudinal changes in phase angle during hospital admission in patients randomised to both arms of INTENT.	Hospital admission (censored at study day 28)
Secondary	Change in bioelectrical impedance spectroscopy (BIS) derived phase angle	Change in BIS-derived phase angle from baseline to hospital discharge and every 7 days between	Every 7 days during hospital admission (censored to study day 28)
Secondary	Change in BIS-derived impedance ratio	Change in BIS-derived impedance ratio from baseline to hospital discharge and every 7 days between.	Every 7 days during hospital admission (censored to study day 28)
Secondary	Change in BIS-derived fat-free mass	Change in BIS-derived fat-free mass (kg) from baseline to hospital discharge and every 7 days between.	Every 7 days during hospital admission (censored to study day 28)
Secondary	Change in BIS-derived normally-hydrated lean tissue	Change in BIS-derived normally-hydrated lean tissue (kg) (generated using the Chamney model) from baseline to hospital discharge and every 7 days between.	Every 7 days during hospital admission (censored to study day 28)
Secondary	Change in BIS-derived Cole model variable R infinity to R0	Change in BIS-derived Cole model variable R infinity to R0 from baseline to hospital discharge and every 7 days between.	Every 7 days during hospital admission (censored to study day 28)
Secondary	Change in BIS-derived characteristic frequency (?c, a Cole model variable)	Change in BIS-derived Cole model variable characteristic frequency (?c) from baseline to hospital discharge and every 7 days between.	Every 7 days during hospital admission (censored to study day 28)
Secondary	Change in BIS-derived membrane capacitance (a Cole model variable)	Change in BIS-derived Cole model variable membrane capacitance from baseline to hospital discharge and every 7 days between.	Every 7 days during hospital admission (censored to study day 28)
Secondary	Change in BIS-derived extra-cellular water	Change in BIS-derived extracellular water from baseline to hospital discharge and every 7 days between.	Every 7 days during hospital admission (censored to study day 28)
Secondary	Change in BIS-derived intracellular water	Change in BIS-derived intracellular water from baseline to hospital discharge and every 7 days between.	Every 7 days during hospital admission (censored to study day 28)
Secondary	Change in ultrasound-derived Rectus femoris cross-sectional area	Change in ultrasound-derived Rectus femoris cross-sectional area (cm2) from baseline to hospital discharge and at measurement points (every 7 days during hospital admission).	Every 7 days during hospital admission (censored to study day 28)
Secondary	Change in ultrasound-derived mid-upper arm muscle thickness	Change in ultrasound-derived muscle thickness (in centimetres) at the mid-upper arm from baseline to hospital discharge and at measurement points (every 7 days during hospital admission).	Every 7 days during hospital admission (censored to study day 28)
Secondary	Change in ultrasound-derived bilateral quadriceps muscle thickness	Change in ultrasound-derived bilateral quadriceps muscle thickness (in centimetres) from baseline to hospital discharge and at measurement points (every 7 days during hospital admission).	Every 7 days during hospital admission (censored to study day 28)
Secondary	Change in ultrasound-derived Rectus femoris echogenicity	Change in ultrasound-derived Rectus femoris echogenicity from baseline to hospital discharge and at measurement points (every 7 days during hospital admission).	Every 7 days during hospital admission (censored to study day 28)
Secondary	Muscle mass at ICU admission	An estimate of whole-body muscularity at ICU admission (enrolment) will be assessed by ultrasound	Baseline (Enrolment)